Milos Kesek

Heart rate variability during sleep and sleep apnoea in a population based study of 387 women

Increased sympathetic activity during sleep has been suggested as a link between obstructive sleep apnoea syndrome and cardiovascular disease. Heart rate variability (HRV) is a measure of autonomic effect on the heart. Different parameters have been associated with sympathetic and parasympathetic activity. We have studied HRV in different sleep stages and related the HRV‐pattern to sleep apnoea in a population‐based sample of 387 women. We investigated the HRV‐parameters standard deviation of all R‐R intervals (SDNN), root of the averaged square of successive differences (RMSSD), low frequency component (LF), high frequency component (HF), ratio of low frequency component to high frequency component LF/HF and VSAI [variation in sympathetic activity between rapid eye movement (REM) and slow wave sleep, defined as LFREM−LFSWS]. The HRV‐parameters were compared with the results of a full‐night polysomnography. Hourly incidence of obstructive episodes was used for classifying the subjects into four apnoea‐hypopnoea index (AHI)‐groups (<5, ≥5 and <15, 15–30 and >30 events). Individual sleep stages were analysed by pooling all recordings. Women with high AHI had higher heart rate and LF/HF ratio. In subjects with AHI >30, LF/HF ratio however dropped to same level as with AHI <5. Subjects with high AHI had low VSAI. Levels of SDNN, LF and LF/HF ratio during REM and light sleep were similar to wakefulness. In slow wave sleep the parameters decreased. In conclusion, moderately increased prevalence of obstructive apnoeas was associated with signs of higher sympathetic activity. High AHI was however associated with a HRV‐pattern suggestive of depressed sympathetic drive and lowered ability to increase it during REM.

Two automatic QT algorithms compared with manual measurement in identification of long QT syndrome.

BACKGROUND Long QT syndrome (LQTS) is an inherited disorder that increases the risk of syncope and malignant ventricular arrhythmias, which may result in sudden death. METHODS We compared manual measurement by 4 observers (QT(manual)) and 3 computerized measurements for QT interval accuracy in the diagnosis of LQTS: 1. QT measured from the vector magnitude calculated from the 3 averaged orthogonal leads X, Y, and Z (QTVCG) and classified using the same predefined QTc cut-points for classification of QT prolongation as in manual measurements; 2. QT measured by a 12-lead electrocardiogram (ECG) program (QTECG) and subsequently classified using the same cut-points as in (1) above; 3. The same QT value as in (2) above, automatically classified by a 12-lead ECG program with thresholds for QT prolongation adjusted for age and sex (QTinterpret). The population consisted of 94 genetically confirmed carriers of KCNQ1 (LQT1) and KCNH2 (LQT2) mutations and a combined control group of 28 genetically confirmed noncarriers and 66 unrelated healthy volunteers. RESULTS QT(VCG) provided the best combination of sensitivity (89%) and specificity (90%) in diagnosing LQTS, with 0.948 as the area under the receiver operating characteristic curve. The evaluation of QT measurement by the 4 observers revealed a high interreader variability, and only 1 of 4 observers showed acceptable level of agreement in LQTS mutation carrier identification (kappa coefficient >0.75). CONCLUSION Automatic QT measurement by the Mida1000/CoroNet system (Ortivus AB, Danderyd, Sweden) is an accurate, efficient, and easily applied method for initial screening for LQTS.

Assessment of Use vs Discontinuation of Oral Anticoagulation After Pulmonary Vein Isolation in Patients With Atrial Fibrillation

Importance Pulmonary vein isolation (PVI) is a recommended treatment for patients with atrial fibrillation, but it is unclear whether it results in a lower risk of stroke. Objectives To investigate the proportion of patients discontinuing anticoagulation treatment after PVI in association with the CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years [doubled], diabetes, stroke [doubled], vascular disease, age 65-74 years, sex category [female]) score, identify factors predicting stroke after PVI, and explore the risk of cardiovascular events after PVI in patients with and without guideline-recommended anticoagulation treatment. Design, Setting, and Participants A retrospective cohort study was conducted using Swedish national health registries from January 1, 2006, to December 31, 2012, with a mean-follow up of 2.6 years. A total of 1585 patients with atrial fibrillation undergoing PVI from the Swedish Catheter Ablation Register were included, with information about exposure to warfarin in the national quality register Auricula. Data analysis was performed from January 1, 2015, to April 30, 2016. Exposures Warfarin treatment. Main Outcomes and Measures Ischemic stroke, intracranial hemorrhage, and death. Results In this cohort of 1585 patients, 73.0% were male, the mean (SD) age was 59.0 (9.4) years, and the mean (SD) CHA2DS2-VASc score was 1.5 (1.4). Of the 1585 patients, 1175 were followed up for more than 1 year after PVI. Of these, 360 (30.6%) discontinued warfarin treatment during the first year. In patients with a CHA2DS2-VASc score of 2 or more, patients discontinuing warfarin treatment had a higher rate of ischemic stroke (5 events in 312 years at risk [1.6% per year]) compared with those continuing warfarin treatment (4 events in 1192 years at risk [0.3% per year]) (P = .046). Patients with a CHA2DS2-VASc score of 2 or more or those who had previously experienced an ischemic stroke displayed a higher risk of stroke if warfarin treatment was discontinued (hazard ratio, 4.6; 95% CI, 1.2-17.2; P = .02 and hazard ratio, 13.7; 95% CI, 2.0-91.9; P = .007, respectively). Conclusions and Relevance These findings indicate that discontinuation of warfarin treatment after PVI is not safe in high-risk patients, especially those who have previously experienced an ischemic stroke.

U22, a Protocol to Quantify Symptoms Associated with Supraventricular Tachycardia

Background: The main indication for ablation of supraventricular tachyarrhythmias (SVTA) is symptomatic relief. Specific paroxysmal symptoms cannot be quantified with general measures of quality of life, such as with the SF‐36 questionnaire. U22 is a new protocol which measures the effects of arrhythmia on well‐being, the intensity of discomfort during an episode, the type and temporal characteristics of dominant symptoms, and the duration and frequency of episodes. Discrete 0–10 scales are used. Unlike SF‐36, U22 can be used in individual patients.

Ablation procedures in Sweden during 2007: results from the Swedish Catheter Ablation Registry

AIMS Catheter ablation research is reported extensively. Much less is known about the clinical practice in the field. Study databases and surveys target selected populations. A general registry is needed to evaluate the actual results of routine catheter ablation. We present statistics from the Swedish Catheter Ablation Registry. METHODS AND RESULTS The registry is a nation-wide database collecting data from all the eight centres serving the countrys population of 9.18 million inhabitants. During each ablation procedure, the data are entered into a local database. On demand, the data are transferred to the central data management facility. The central SQL-database presently covers 7018 ablations performed in 5885 patients during 2004-07. In 2007, 2314 ablation procedures [521 for atrial fibrillation (AF)] were performed (252 ablations per million inhabitants and 57 AF procedures per million inhabitants). Mean procedure and fluoroscopy times ranked from 75 and 12 min, respectively, for atrioventricular junction ablation to 224 and 43 min, respectively, for AF ablation. The incidence of complications during 2007 was 1.8%. One death after a procedure for AF was reported, due to a cerebrovascular embolus. CONCLUSION The report presents prospective-gathered annual data from a nation-wide ablation register with voluntary participation. Several major complications have been reported, but the overall complication rate was low.

Symptomatic improvement after catheter ablation of supraventricular tachycardia measured by the arrhythmia-specific questionnaire U22

Abstract Introduction. The main indication for ablation of supraventricular tachycardia is symptomatic relief. Generic measures of quality of life are not suitable for direct evaluation of arrhythmia-related symptoms, and a specific tool is needed. The questionnaire U22 quantifies symptoms associated with arrhythmic events. It uses discrete 0–10 scales for quantification of influence of arrhythmia on well-being, intensity of discomfort, type of dominant symptom, and a time aspect that summarizes duration and frequency of spells. We evaluated U22 in a well defined group of patients with paroxysmal supraventricular tachycardia, undergoing an intervention with a distinct end-point and a high success rate. Methods. Symptoms in patients with accessory pathway and atrioventricular nodal re-entrant tachycardia scheduled for ablation were measured with U22 and SF-36 on admission. The evaluation was repeated after 6 months. Results. Altogether 58 patients successfully ablated in 2006–2008 completed the four forms (U22 and SF-36 at base-line and follow-up, 210 ± 35 days after ablation). The score for well-being (0–10; 10 being best) increased from 5.9 ± 2.6 to 7.9 ± 1.9 (P < 0.0005). The score for arrhythmia as cause for impairment in well-being (0–10; 10 being highest) decreased from 7.5 ± 2.8 to 2.0 ± 3.1 (P < 0.0005). The time aspect score (0–10) decreased from 4.7 ± 1.5 to 1.4 ± 1.8 (P < 0.0005). The two SF-36 summary measures PCS and MCS increased from 46.9 ± 9.4 to 48.4 ± 10.7 and from 44.9 ± 12.5 to 49.1 ± 9.9 (P = 0.04 and 0.002). Conclusion. After successful ablation of accessory pathway and atrioventricular nodal re-entrant tachycardia, the U22 protocol detected a relevant increase in arrhythmia-related well-being. Modest improvement in general well-being was detected by the SF-36 protocol.

Right ventricular lead positioning does not influence the benefits of cardiac resynchronization therapy in patients with heart failure and atrial fibrillation

AIMS Little is known about the optimal right ventricular (RV) pacing site in cardiac resynchronization therapy (CRT). This study compares bi-ventricular pacing at the left ventricular (LV) free wall combined with two different RV stimulation sites: RV outflow tract (RVOT+LV) vs. RV-apex (RVA+LV). METHODS AND RESULTS Thirty-three patients (32 males) with chronic heart failure, NYHA class III-IV, optimal drug therapy, QRS-duration ≥150 ms, and chronic atrial fibrillation (AF) received CRT with two different RV leads, in the apex (RVA) or outflow tract (RVOT), together with an LV lead, all connected to a bi-ventricular pacemaker. Randomization to pacing in RVOT+LV or RVA+LV was made 1 month after implantation and cross-over to the alternate pacing configuration occurred after 3 months. The median age of patients was 69 ± 10 years, the mean QRS was 179 ± 23 ms, and 58% of patients had ischaemic heart disease. Seven patients had pacemaker rhythm at inclusion and 60% were treated with atrioventricular-junctional ablation before randomization. In the RVA+LV and RVOT+LV pacing modes, 67 and 63% (nonsignificant) responded symptomatically with a decrease of at least 10 points in the Minnesota Living with Heart Failure score. The secondary end-points (6-min walk test, peak oxygen uptake, N-Terminal fragment of B-type Natriuretic Peptide, and left ventricular ejection fraction) showed significant improvement between baseline and CRT, but not between RVOT+LV and RVA+LV. CONCLUSION In this randomized controlled study, the exact RV pacing site, either apex or outflow tract, did not influence the benefits of CRT in a group of patients with chronic heart failure and AF. ClinicalTrials.gov ID: NCT00457834.

Autonomic denervation after the Maze procedure.

LÖNNERHOLM, S., et al.: Autonomic Denervation After the Maze Procedure. The Maze III procedure is a surgical operation for curative treatment of AF. The procedure is extensive, however, with multiple incisions in both atria, and its effects on autonomic regulation of the heart rhythm are not known. This study comprises 17 patients, 10 with paroxysmal AF and 7 with chronic AF, who had no concurrent cardiac disease known to affect heart rate variability (HRV). A 24‐hour Holter recording was performed preoperatively and 2 months (early) and 7 months (late) after surgery, for analysis of HRV in the time and frequency domains. Early after the Maze procedure all HRV components were markedly reduced compared to baseline (mean ± 1 SD): SDNN 73 ± 13 versus 148 ± 50 (ms), total power 168 ± 126 versus 560 ± 1567 (ms2), low frequency (LF) power 47 ± 67 versus 826 ± 677 (ms2), high frequency (HF) power 47 ± 40 versus 678 ± 666 (ms2), and LF:HF 1.22 ± 0.9 versus 2.55 ± 1.4 . Late after the Maze procedure all variables were still reduced. Only total power increased significantly between early and late follow‐up ( 168 ± 126 vs 496 ± 435 ms2). Late after Maze surgery, values of the different HRV components did not differ between the patients with paroxysmal AF and chronic AF. Early after the Maze procedure there is a marked decrease of all HRV components, which is maintained 7 months after surgery, a pattern consistent with denervation of the heart. (PACE 2003; 26[Pt. I]:587–592)

Radiotherapy and pacemaker : 80 Gy to target close to the device may be feasible.

Modern pacemakers using complementary metal-oxide semiconductors (CMOS) technology are sensitive to radiation. The guidelines recommend caution at doses above 2 Gray (Gy). Repositioning should be discussed if cumulative dose and dose rate exceeds 10 and 0.2 Gy/min. We report a case of a man with mechanical mitral valve prosthesis and pacemaker due to sick sinus syndrome …

Principal component analysis of the T-wave in patients with chest pain and conduction disturbances.

There is a need for markers reflecting the increased risk in patients with conduction disturbances. Conduction disturbances presumably cause inhomogeneous repolarization that may create an arrhythmogenic substrate. In patients with normal conduction, parameters derived from principal components analysis (PCA) of the T wave contain prognostic information. The nondipolar PCA components are assumed to reflect repolarization inhomogeneity. This study examined the PCA parameters in relation to conduction disturbances. PCA was performed on continuously recorded 12‐lead ECGs in 800 patients with chest pain and nondiagnostic ECG on admission. The patients with conduction disturbance on admission were classified into separate groups and related to comparison groups without conduction disturbance recruited from the same series. For each patient, the dipolar and nondipolar components were quantified by medians of the ratio of the two largest eigenvalues (S2/S1 Median), the residue that summarizes the eigenvalues S4–S8 (TWRabsMedian) and the ratio of this residue to the total power of the T wave (TWRrelMedian). The parameters were assessed with respect to common clinical and ECG parameters, discharge diagnosis, and total mortality during a 35‐month follow‐up. TWRabsMedian increased with increasing conduction disturbance. In 135 patients with conduction disturbances, ROC curves for TWRabsMedian as indicator of mortality exhibited areas under a curve of 0.66, 0.65, and 0.56 at 6‐month, 24‐month, and 35‐month follow‐up. Conduction disturbances were associated with increased nondipolar PCA component and, thus, with increased repolarization inhomogeneity. The nondipolar PCA component contained a moderate amount of prognostic information not present in a simple ECG diagnosis of a conduction disturbance.